Pharmacodynamics of RP 59500 (quinupristin-dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus- infected fibrin-platelet clots in an in vitro infection model

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 6, 1997, Pages 1359-1363

  Rybak, Michael J ^a,b,c   Houlihan, Heather H ^a,b   Mercier, Renee Claude ^a,b   Kaatz, Glenn W ^b,c  

^a DETROIT RECEIVING HOSPITAL   (United States)

^b WSU   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALFOPRISTIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; METICILLIN; QUINUPRISTIN;

AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; CONTINUOUS INFUSION; FIBRIN CLOT; HUMAN; HUMAN CELL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; THROMBOCYTE AGGREGATION;

EID: 0030920562     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.6.1359     Document Type: Article

References (24)

1. Aden, S. D., S. Chevret, P. Vinceneux, I. Cazenave, A. Frydman, and J. J. Garaud. 1992. A phase I, double-blind, placebo-controlled study of the tolerance and pharmacokinetic behavior of RP 59500. J. Antimicrob. Chemother. 30(Suppl. A.):123-131.
2. Barriere, J. C., D. H. Bounanchaud, J. M. Paris, O. Rollin, N. V. Harris, and C. Smith. 1992. Antimicrobial activity against Staphylococcus aureus of semisynthetic injectable streptogramins: RP 59500 and related compounds. J. Antimicrob. Chemother. 30(Suppl. A):1-8.
3. Brumfitt, W., J. M. T. Hamilton-Miller, and S. Shah. 1992. In vitro activity of RP 59500, a new semisynthetic streptogramin antibiotic, against gram-positive bacteria. J. Antimicrob. Chemother. 30(Suppl. A):29-37.
4. Chant, C., and M. J. Rybak. 1995. Quinupristin/dalfopristin (RP 59500): a new streptogramin antibiotic. Ann. Pharmacother. 29:1022-1027.
5. Craig, W. A., and S. Gudmundsson. 1991. The postantibiotic effect, p. 403-431. In V. Lorian (ed.), Antibiotics in laboratory medicine, 3rd ed. Williams and Wilkins Co., Baltimore, Md.
6. Cremieux, A. C., and C. Carbon. 1992. Pharmacokinetic and pharmacodynamic requirements for antibiotic therapy of experimental endocarditis. Antimicrob. Agents Chemother. 36:2069-2074.
7. Entenza, J. M., H. Drugeon, M. P. Glauser, and P. Moreillon. 1995. Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500. Antimicrob. Agents Chemother. 39:1419-1424.
8. Fantin, B., R. Leclercq, Y. Merlé, L. Saint-Julien, C. Veyrat, J. Duval, and C. Carbon. 1995. Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus. Antimicrob. Agents Chemother. 39:400-405.
9. 14C RP 59500 throughout infected cardiac vegetation in rabbits, abstr. 161, p. 149. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
10. Fass, R. J. 1991. In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci. Antimicrob. Agents Chemother. 35:553-559.
11. Kang, S. L., and M. J. Rybak. 1995. Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin clot model. Antimicrob. Agents Chemother. 39:1505-1511.
12. Leclercq, R., and P. Courvalin. 1991. Intrinsic and unusual resistance to macrolide, lincosamide, and streptogramin antibiotics in bacteria. Antimicrob. Agents Chemother. 35:1273-1276.
13. Leclercq, R., L. Nantas, C. J. Soussy, and J. Duval. 1992. Activity of RP 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics. J. Antimicrob. Chemother. 30(Suppl. A):67-75.
14. Lorian, V., L. Amaral, and F. Fernandes. 1995. RP 59500 postantibiotic effect defined by bacterial ultrastructure. Drugs Exp. Clin. Res. 21:125-128.
15. Low, D. E. 1995. Quinupristin/dalfopristin: spectrum of activity, pharmacokinetics, and initial clinical experience. Microb. Drug Resist. 1:223-234.
16. McGrath, B. J., S. L. Kang, G. W. Kaatz, and M. J. Rybak. 1994. Teicoplanin, vancomycin, and gentamicin bactericidal activity alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of infective endocarditis. Antimicrob. Agents Chemother. 38:2034-2040.
17. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 3rd ed. Approved standard M7-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
18. Nougayrede, A., N. Berthaud, and D. H. Bouanchaud. 1992. Post-antibiotic effects of RP 59500 with Staphylococcus aureus. J. Antimicrob. Chemother. 30:101-106.
19. Rocci, M. L., Jr., and W. J. Jusko. 1983. LAGRAN program version 2.1 for area and moments in pharmacokinetic analysis. Comput. Programs Biomed. 16:203-216.
20. Sanchez, M. L., K. K. Flint, and R. N. Jones. 1993. Occurrence of macrolide-lincosamide-streptogramin resistances among staphylococcal clinical isolates at a university medical center. Diagn. Microbiol. Infect. Dis. 16:205-213.
21. Siedentop, K. H., D. M. Harris, K. Ham, and M. L. Sanchez. 1986. Extended experimental and preliminary surgical findings with autologous fibrin tissue adhesive made from patient's own blood. Laryngoscope 96:1062-1064.
22. Simon, H. J., and E. J. Yin. 1970. Microbioassay of antimicrobial agents. Appl. Microbiol. 19:573-579.
23. Thompson, D. F., N. A. Letassy, and G. D. Thompson. 1988. Fibrin glue: a review of its preparation, efficacy, and adverse effects as a topical hemostat. Drug Intell. Clin. Pharm. 34:946-952.
24. Turcotte, A., and M. G. Bergeron. 1992. Penetration and in vivo activity of RP 57669/RP 54476 (RP), a new semi-synthetic streptogramin, in pre-infected, pre-inflammed (sic) fibrin clots, abstr. 1316, p. 330. In Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.